ARVN Arvinas, Inc.
QT35Latest market price
7.86
-0.04-0.51%
TA
Loading chart...
Snapshot
| Index | — | P/E | 49.13 | EPS (ttm) | 0.16 | Insider Own | 15.34% | Shs Outstand | 64.52M | Perf Week | 7.67% |
| Market Cap | 507.14M | Forward P/E | — | EPS next Y | -3.32 | Insider Trans | -0.55% | Shs Float | 56.81M | Perf Month | 5.79% |
| Enterprise Value | 421.04M | PEG | — | EPS next Q | -0.87 | Short Float | 9.84% | Perf Quarter | -2.48% | ||
| Income | 9.00M | P/S | 1.59 | EPS this Y | — | Short Ratio | 6.98 | Perf Half Y | -25.21% | ||
| Sales | 318.00M | P/B | 0.90 | EPS next Y | — | ROA | 1.38% | Short Interest | 5.59M | Perf YTD | -33.73% |
| Book/sh | 8.71 | P/C | 0.89 | EPS next 5Y | — | ROE | 1.91% | 52W High | 14.51 -45.83% | Perf Year | -18.04% |
| Cash/sh | 8.80 | P/FCF | — | EPS past 3/5Y | — | ROIC | -2.18% | 52W Low | 6.74 16.62% | Perf 3Y | -45.53% |
| Dividend Est. | — | EV/EBITDA | 107.96 | Sales past 3/5Y | 26.15% 58.85% | Gross Margin | 96.43% | Volatility | 4.14% 4.48% | Perf 5Y | -90.74% |
| Dividend TTM | — | EV/Sales | 1.33 | EPS Y/Y TTM | — | Oper. Margin | -4.45% | ATR (14) | 0.35 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 7.91 | Sales Y/Y TTM | -14.52% | Profit Margin | 2.94% | RSI (14) | 54.57 | Recom | 2.31 |
| Dividend Gr. 3/5Y | — | Current Ratio | 7.91 | EPS Q/Q | 407.14% | SMA20 | 6.05% | Beta | 1.78 | Target Price | 14.17 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 1036.36% | SMA50 | -2.98% | Rel Volume | 1.36 | Prev Close | 7.90 |
| Employees | 246 | LT Debt/Eq | 0.01 | Earnings | Nov 03 | SMA200 | -18.85% | Avg Volume | 829.55K | Price | 7.86 |
| IPO Date | Sep 27, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 789.64% — | Net Debt/EBITDA | -112.40 | Volume | 1,125,550 | Change | -0.51% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | Morgan Stanley | Equal Weight | $11 → $10 |
| Aug-10-26 | Reiterated | Evercore ISI Group | Outperform | $14 |
| Aug-05-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $11 |
| Aug-05-26 | Reiterated | Wedbush | Neutral | $11 → $12 |
| May-13-26 | Reiterated | Barclays | Overweight | $18 → $20 |
| May-13-26 | Reiterated | BTIG | Buy | $14 → $18 |
| Mar-18-26 | Reiterated | Truist Financial | Hold | $11 → $10 |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy | |
| Dec-17-25 | Reiterated | Barclays | Overweight | $16 → $18 |
| Oct-30-25 | Reiterated | BTIG | Buy | $10 → $14 |
Latest News· Times ET
Oct-27-26
Oct-27-2604:01PM
07:00AM
Oct-19-26
Oct-13-26
Oct-07-26
Oct-07-2607:00AM
Oct-01-26
Oct-01-2604:01PM
Sep-29-26
Sep-29-2604:01PM
Sep-28-26
Sep-28-2607:00AM
Sep-25-26
Sep-18-26
Sep-16-26
Sep-16-2604:11PM
Sep-09-26
Sep-03-26
Sep-01-26
Sep-01-2604:01PM
Aug-30-26
Aug-30-2604:26AM
Company
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 318 | 263 | 263 | 79 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11 | 5 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 306 | 257 | 263 | 79 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 85 | 89 | 165 | 100 | — | — | — | — | — | |
| Research and Development | 239 | 283 | 348 | 380 | — | — | — | — | — | |
| Other Operating Expense | -4 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -15 | -115 | -250 | -401 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 25 | 34 | 52 | 35 | — | — | — | — | — | |
| Net Income Before Taxes | 11 | -80 | -198 | -366 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 1 | 1 | — | — | — | — | — | |
| Consolidated Net Income | 9 | -81 | -199 | -367 | — | — | — | — | — | |
| Net Income From Continuing Operations | 9 | -81 | -199 | -367 | — | — | — | — | — | |
| Net Income | 9 | -81 | -199 | -367 | — | — | — | — | — | |
| EPS (Recurring) | 0.19 | -1.28 | -2.77 | -6.62 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.19 | -1.28 | -2.77 | -6.62 | — | — | — | — | — | |
| EPS (Diluted) | 0.16 | -1.28 | -2.77 | -6.62 | — | — | — | — | — | |
| EBITDA | 5 | -75 | -192 | -360 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 49.13 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.61 | 2.93 | 5.25 | 29.18 | — | — | — | — | — | |
| Gross Margin | 96.23 | 97.72 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -4.72 | -43.73 | -95.06 | -507.59 | — | — | — | — | — | |
| Net Margin | 2.83 | -30.80 | -75.67 | -464.56 | — | — | — | — | — | |
| Shares Outstanding | 65 | 65 | 72 | 56 | — | — | — | — | — | |
| Market Capitalization | 511 | 771 | 1,380 | 2,305 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Saik Andrew | Chief Financial Officer | Jun 24 '26 | Sale | 8.16 | 5,696 | 46,474 | 187,432 | Jun 24 |
| Cacace Angela M | Chief Scientific Officer | Jun 17 '26 | Sale | 7.59 | 2,576 | 19,565 | 180,390 | Jun 18 |
| Teel Randy | President and CEO | May 21 '26 | Sale | 9.04 | 2,209 | 19,962 | 285,009 | May 22 |
| Cacace Angela M | Chief Scientific Officer | May 11 '26 | Sale | 9.94 | 9,657 | 95,965 | 182,966 | May 13 |
| Berkowitz Noah | Chief Medical Officer | May 11 '26 | Sale | 9.94 | 11,108 | 110,385 | 191,395 | May 13 |
| Teel Randy | President and CEO | May 11 '26 | Sale | 9.94 | 9,657 | 95,965 | 287,218 | May 13 |
| Saik Andrew | Chief Financial Officer | May 11 '26 | Sale | 9.94 | 11,139 | 110,693 | 193,128 | May 13 |
| Loomis David K | VP, Chief Accounting Officer | May 11 '26 | Sale | 9.94 | 1,919 | 19,070 | 40,193 | May 13 |
| Berkowitz Noah | Chief Medical Officer | Mar 18 '26 | Sale | 11.10 | 6,435 | 71,431 | 202,503 | Mar 19 |
| Morrison Briggs | Director | Mar 06 '26 | Buy | 13.40 | 20,000 | 268,070 | 96,021 | Mar 09 |
| Houston John G | Director | Feb 27 '26 | Sale | 13.21 | 35,297 | 466,153 | 1,122,183 | Mar 02 |
| Loomis David K | Chief Accounting Officer | Feb 23 '26 | Sale | 12.16 | 1,108 | 13,473 | 29,692 | Feb 25 |
| Cacace Angela M | Chief Scientific Officer | Feb 23 '26 | Sale | 12.16 | 3,609 | 43,885 | 147,623 | Feb 25 |
| Teel Randy | President and CEO | Feb 23 '26 | Sale | 12.16 | 4,786 | 58,198 | 149,696 | Feb 25 |
| Teel Randy | President and CEO | Feb 13 '26 | Sale | 11.89 | 4,403 | 52,352 | 154,482 | Feb 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.